Bacterial ghosts (BGs)-Advanced antigen and drug delivery system

Vaccine

Volumn 28, Issue 36, 2010, Pages 5760-5767

  Kudela, Pavol ^a,c   Koller, Verena Juliana ^a   Lubitz, Werner ^a,b  

^a BIRD C GmbH and CoKEG   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

^c CANCER RESEARCH INSTITUTE   (Slovakia)

Author keywords

Bacterial ghosts; Cancer therapy; Delivery system; Toxicity; Vaccine

Indexed keywords

BACTERIAL GHOST; BACTERIAL VACCINE; DENDRITIC CELL VACCINE; DNA VACCINE; DOXORUBICIN; DRUG CARRIER; HEPATITIS B CORE ANTIGEN; HEPATITIS B CORE ANTIGEN 149; OUTER MEMBRANE PROTEIN A; TOLL LIKE RECEPTOR 4; TUMOR VACCINE; UNCLASSIFIED DRUG;

ACTINOBACILLUS PLEUROPNEUMONIAE; ANTIGEN PRESENTATION; BACTERIAL MEMBRANE; CELL NUCLEUS; CELL PROLIFERATION; CELL VIABILITY; CELLULAR IMMUNITY; DNA VECTOR; DRUG DELIVERY SYSTEM; DRUG RELEASE; ENTEROHEMORRHAGIC ESCHERICHIA COLI; ESCHERICHIA COLI; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HUMORAL IMMUNITY; LEUKEMIA CELL; MANNHEIMIA HAEMOLYTICA; MELANOMA CELL; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; REVIEW; SALMONELLA ENTERICA; SHIGELLA FLEXNERI; VIBRIO CHOLERAE;

ANTINEOPLASTIC AGENTS; CACO-2 CELLS; CANCER VACCINES; CELL PROLIFERATION; DNA; DOXORUBICIN; DRUG DELIVERY SYSTEMS; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GRAM-NEGATIVE BACTERIA; HUMANS; LEUKEMIA; MELANOMA; PHAGOCYTOSIS;

EID: 77955557497     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.06.087     Document Type: Review

References (44)

1. Gentschev I., Dietrich G., Spreng S., Kolb-Maurer A., Brinkmann V., Grode L., et al. Recombinant attenuated bacteria for the delivery of subunit vaccines. Vaccine 2001 Mar 21, 19(17-19):2621-2628.
2. Jager E., Karbach J., Gnjatic S., Neumann A., Bender A., Valmori D., et al. Recombinant vaccinia/fowipox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proceedings of the National Academy of Sciences of the United States of America 2006, 103(39):14453-14458.
3. Nishikawa H., Tsuji T., Jager E., Briones G., Ritter G., Old L.J., et al. Induction of regulatory T cell-resistant helper CD4+ T cells by bacterial vector. Blood 2008 Feb 1, 111(3):1404-1412.
4. Reschel T., Konak C., Oupicky D., Seymour L.W., Ulbrich K. Physical properties and in vitro transfection efficiency of gene delivery vectors based on complexes of DNA with synthetic polycations. J Control Release 2002 May 17, 81(1-2):201-217.
5. Schnell S., Young J.W., Houghton A.N., Sadelain M. Retrovirally transduced mouse dendritic cells require CD4+ T cell help to elicit antitumor immunity: Implications for the clinical use of dendritic cells. J Immunol 2000 Feb 1, 164(3):1243-1250.
6. Schumacher L., Ribas A., Dissette V.B., McBride W.H., Mukherji B., Economou J.S., et al. Human dendritic cell maturation by adenovirus transduction enhances tumor antigen-specific T-cell responses. J Immunother 2004, 27(May-June (3)):191-200.
7. Medina E., Guzman C.A. Use of live bacterial vaccine vectors for antigen delivery: potential and limitations. Vaccine 2001, 19(February (13-14)):1573-1580.
8. Mengesha A., Dubois L., Chiu R.K., Paesmans K., Wouters B.G., Lambin P., et al. Potential and limitations of bacterial-mediated cancer therapy. Front Biosci 2007, 12:3880-3891.
9. Viale P.H., Yamamoto D.S. Cardiovascular toxicity associated with cancer treatment. Clin J Oncol Nurs 2008, 12(August (4)):627-638.
10. Yeh E.T. Cardiotoxicity induced by chemotherapy and antibody therapy. Annu Rev Med 2006, 57:485-498.
11. Tawbi H.A., Kirkwood J.M. Management of metastatic melanoma. Semin Oncol 2007, 34(December (6)):532-545.
12. Lubitz W. Bacterial ghosts as carrier and targeting systems. Expert Opin Biol Ther 2001, 1(September (5)):765-771.
13. Paukner S., Stiedl T., Kudela P., Bizik J., Al Laham F., Lubitz W. Bacterial ghosts as a novel advanced targeting system for drug and DNA delivery. Expert Opin Drug Deliv 2006, 3(January (1)):11-22.
14. Tabrizi C.A., Walcher P., Mayr U.B., Stiedl T., Binder M., McGrath J., et al. Bacterial ghosts-biological particles as delivery systems for antigens, nucleic acids and drugs. Curr Opin Biotechnol 2004, 15(December (6)):530-537.
15. Mayr B., Koller V.J., Lubitz P., Lubitz W. Bacterial ghosts as vaccine and drug delivery platforms. Patho-Biotechnology 2008, 50-59. Landes Bioscience, Austin. R. Sleator, C. Hill (Eds.).
16. Panthel K., Jechlinger W., Matis A., Rohde M., Szostak M., Lubitz W., et al. Generation of Helicobacter pylori ghosts by PhiX protein E-mediated inactivation and their evaluation as vaccine candidates. Infect Immun 2003, 71(January (1)):109-116.
17. Jechlinger W., Haller C., Resch S., Hofmann A., Szostak M.P., Lubitz W. Comparative immunogenicity of the hepatitis B virus core 149 antigen displayed on the inner and outer membrane of bacterial ghosts. Vaccine 2005, 23(May (27)):3609-3617.
18. Witte A., Wanner G., Sulzner M., Lubitz W. Dynamics of PhiX174 protein E-mediated lysis of Escherichia coli. Arch Microbiol 1992, 157(4):381-388.
19. Mader H.J., Szostak M.P., Hensel A., Lubitz W., Haslberger A.G. Endotoxicity does not limit the use of bacterial ghosts as candidate vaccines. Vaccine 1997, 15(February (2)):195-202.
20. Paukner S., Kohl G., Lubitz W. Bacterial ghosts as novel advanced drug delivery systems: antiproliferative activity of loaded doxorubicin in human Caco-2 cells. J Control Release 2004, 94(January (1)):63-74.
21. Kudela P., Paukner S., Mayr U.B., Cholujova D., Kohl G., Schwarczova Z., et al. Effective gene transfer to melanoma cells using bacterial ghosts. Cancer Lett 2008, 262(1):54-63.
22. Kudela P., Paukner S., Mayr U.B., Cholujova D., Schwarczova Z., Sedlak J., et al. Bacterial ghosts as novel efficient targeting vehicles for DNA delivery to the human monocyte-derived dendritic cells. J Immunother 2005, 28(March-April (2)):136-143.
23. Paukner S., Kudela P., Kohl G., Schlapp T., Friedrichs S., Lubitz W. DNA-loaded bacterial ghosts efficiently mediate reporter gene transfer and expression in macrophages. Mol Ther 2005, 11(February (2)):215-223.
24. Ebensen T., Paukner S., Link C., Kudela P., de Domenico C., Lubitz W., et al. Bacterial ghosts are an efficient delivery system for DNA vaccines. J Immunol 2004, 172(June (11)):6858-6865.
25. Trombetta E.S., Mellman I. Cell biology of antigen processing in vitro and in vivo. Ann Rev Immunol 2005, 23:975-1028.
26. Trombetta E.S., Ebersold M., Garrett W., Pypaert M., Mellman I. Activation of lysosomal function during dendritic cell maturation. Science 2003 Feb 28, 299(5611):1400-1403.
27. Brady M.S., Lee F., Petrie H., Eckels D.D., Lee J.S. CD4(+) T cells kill HLA-class-II-antigen-positive melanoma cells presenting peptide in vitro. Cancer Immunol Immunother 2000, 48(February (11)):621-626.
28. Curiel-Lewandrowski C., Demierre M.F. Advances in specific immunotherapy of malignant melanoma. J Am Acad Dermatol 2000, 43(August (2 Pt 1)):167-185. [quiz 86-88].
29. Lugini L., Matarrese P., Tinari A., Lozupone F., Federici C., Iessi E., et al. Cannibalism of live lymphocytes by human metastatic but not primary melanoma cells. Cancer Res 2006, 66(April (7)):3629-3638.
30. Molteni M., Marabella D., Orlandi C., Rossetti C. Melanoma cell lines are responsive in vitro to lipopolysaccharide and express TLR-4. Cancer Lett 2006, 235(April (1)):75-83.
31. Dunzendorfer S., Lee H.K., Soldau K., Tobias P.S. TLR4 is the signaling but not the lipopolysaccharide uptake receptor. J Immunol 2004, 173(July (2)):1166-1170.
32. Huang B., Zhao J., Li H., He K.L., Chen Y., Chen S.H., et al. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res 2005, 65(June (12)):5009-5014.
33. Kelly M.G., Alvero A.B., Chen R., Silasi D.A., Abrahams V.M., Chan S., et al. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res 2006, 66(April (7)):3859-3868.
34. Bauer A.K., Dixon D., DeGraff L.M., Cho H.Y., Walker C.R., Malkinson A.M., et al. Toll-like receptor 4 in butylated hydroxytoluene-induced mouse pulmonary inflammation and tumorigenesis. J Natl Cancer Inst 2005, 97(December (23)):1778-1781.
35. Andreani V., Gatti G., Simonella L., Rivero V., Maccioni M. Activation of Toll-like receptor 4 on tumor cells in vitro inhibits subsequent tumor growth in vivo. Cancer Res 2007, 67(November (21)):10519-10527.
36. Lee C.H., Wu C.L., Shiau A.L. Toll-like receptor 4 mediates an antitumor host response induced by Salmonella choleraesuis. Clin Cancer Res 2008, 14(March (6)):1905-1912.
37. Makhey V.D., Guo A., Norris D.A., Hu P., Yan J., Sinko P.J. Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells. Pharm Res 1998, 15(August (8)):1160-1167.
38. Suzuki H., Sugiyama Y. Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine. Eur J Pharm Sci 2000, 12(November (1)):3-12.
39. Wolff J.A., Budker V. The mechanism of naked DNA uptake and expression. Adv Genet 2005, 54:3-20.
40. Wolff J.A., Ludtke J.J., Acsadi G., Williams P., Jani A. Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle. Hum Mol Genet 1992, 1(September (6)):363-369.
41. Yu M., Finn O.J. DNA vaccines for cancer too. Cancer Immunol Immunother 2006, 55(February (2)):119-130.
42. Lugini L., Lozupone F., Matarrese P., Funaro C., Luciani F., Malorni W., et al. Potent phagocytic activity discriminates metastatic and primary human malignant melanomas: a key role of ezrin. Lab Invest 2003, 83(November (11)):1555-1567.
43. Jechlinger W., Azimpour Tabrizi C., Lubitz W., Mayrhofer P. Minicircle DNA immobilized in bacterial ghosts: in vivo production of safe non-viral DNA delivery vehicles. J Mol Microbiol Biotechnol 2004, 8(4):222-231.
44. Mayrhofer P., Tabrizi C.A., Walcher P., Haidinger W., Jechlinger W., Lubitz W. Immobilization of plasmid DNA in bacterial ghosts. J Control Release 2005 Feb 16, 102(3):725-735.